The FOXO4-DRI sequence is a D-retro-inverso peptide derived from FOXO4. Learn what the sequence means, how it's used in research, and key safety facts.
The FOXO4-DRI sequence is the amino acid sequence of a D-retro-inverso peptide derived from the FOXO4 protein. It is a synthetic peptide designed to interfere with the FOXO4–p53 interaction, which helps senescent cells survive. The "DRI" stands for D-retro-inverso, meaning the peptide is built from D-amino acids in the reverse order of the native FOXO4 fragment.
What Is the FOXO4-DRI Sequence?
FOXO4-DRI is a synthetic peptide. Its sequence is not a naturally occurring string of amino acids. Instead, it is a mirror-image, reverse-order version of a short segment of the human FOXO4 protein.
In practical terms, the FOXO4-DRI sequence is often described as a 22-amino acid peptide. The exact sequence is published in the scientific literature, and it is usually written using D-amino acid abbreviations. Researchers who need the precise sequence should refer to the original 2017 Cell paper by Baar and colleagues.
Because the peptide uses D-amino acids, it is more stable in the body than a typical L-amino acid peptide. That stability is one reason the FOXO4-DRI sequence has attracted attention in aging research.
It is also worth noting that FOXO4-DRI is sometimes called Proxofim. This is the name used by the company developing it for potential clinical applications. Regardless of the name, the sequence remains the same D-retro-inverso design.
How the D-Retro-Inverso Design Works
The term "D-retro-inverso" describes two changes made to a natural peptide sequence. First, the order of the amino acids is reversed. Second, each L-amino acid is replaced with its D-amino acid mirror image.
This design is often used to create a foxo4 d retro inverso dri peptide that resists rapid breakdown by enzymes. The result is a peptide that can mimic the shape of the original FOXO4 fragment while lasting longer in biological systems.
The native FOXO4 protein binds to p53 and helps keep senescent cells from undergoing apoptosis. The FOXO4-DRI peptide interferes with that interaction, which can trigger senescent cells to die. This mechanism is why FOXO4-DRI is classified as a senolytic compound in research settings.
Enzymes in the body, called proteases, normally recognize and cut L-amino acid peptides. Because D-amino acids are mirror images, proteases do not recognize them as easily. This is the main reason the D-retro-inverso design is used for FOXO4-DRI.
FOXO4-DRI in Research and Human Trials
Most of the evidence for FOXO4-DRI comes from laboratory and animal studies. In mice, the peptide has been shown to clear senescent cells and improve markers of aging, including kidney function and fur density.
As of now, there are no completed foxo4-dri human trials published in peer-reviewed journals. The peptide has not been approved by the FDA for any human use. Any claims about human benefits are speculative and should be treated with caution.
Researchers continue to study senolytic peptides like FOXO4-DRI because they may offer a targeted way to address age-related cellular dysfunction. However, the jump from mouse studies to human therapies is large and uncertain.
Senescent cells accumulate with age and contribute to inflammation and tissue dysfunction. Targeting them with senolytics is an active area of research. FOXO4-DRI is one of several compounds being explored, but it is not yet ready for clinical use.
FOXO4-DRI Dosage and Safety
There is no established foxo4-dri dosage for humans. Because the peptide is not approved for clinical use, no standard dosing guidelines exist. Any dosage information found online is based on anecdotal reports or animal studies, not controlled human trials.
Some people search for a dosage calculator or discuss bodybuilding forums. These discussions are not supported by medical evidence. Using unapproved peptides carries unknown risks.
Potential foxo4-dri side effects are not well characterized in humans. Because the peptide affects p53-related pathways, there are theoretical concerns about unintended effects on normal cells. Anyone considering such compounds should consult a licensed healthcare professional.
You may also find foxo4-dri reviews online. These are anecdotal and should not be used as a basis for medical decisions.
Regulatory agencies have not approved FOXO4-DRI for any indication. In the United States, the FDA does not allow the sale of unapproved peptides for human consumption. This means any FOXO4-DRI sold online is likely intended for research use only.
Key Features of the FOXO4-DRI Sequence
- D-amino acids: The sequence uses D-amino acids instead of the L-amino acids found in natural proteins.
- Reversed order: The amino acid order is reversed compared to the native FOXO4 fragment.
- 22 amino acids: The peptide is typically described as a 22-amino acid chain.
- Senolytic mechanism: The sequence is designed to disrupt the FOXO4–p53 interaction in senescent cells.
- Research use only: The peptide is not approved for human use and is sold for laboratory research.
How to Find the Exact FOXO4-DRI Sequence
If you need the precise amino acid sequence, follow these steps:
- Locate the 2017 Cell paper titled "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging."
- Check the supplementary materials for the peptide sequence.
- Look for the D-retro-inverso version written with D-amino acid abbreviations.
- Cross-reference with peptide vendor certificates of analysis for research-grade FOXO4-DRI.
Be careful with unofficial sources. Some websites list incorrect or incomplete sequences. Always verify with the primary literature or a reputable peptide supplier.
FOXO4-DRI Sequence at a Glance
| Feature | Native FOXO4 Fragment | FOXO4-DRI |
|---|---|---|
| Amino acid stereochemistry | L-amino acids | D-amino acids |
| Sequence order | Natural order | Reversed order |
| Stability in body | Low | Higher |
| Primary use | Natural binding research | Senolytic research |
Understanding the FOXO4-DRI sequence helps clarify why this peptide is studied as a senolytic. The D-retro-inverso design is the key feature that distinguishes it from the natural FOXO4 fragment. However, research is still in early stages, and no human therapy exists.
Frequently Asked Questions
What is the exact amino acid sequence of FOXO4-DRI?
FOXO4-DRI is a 22-amino acid D-retro-inverso peptide based on a fragment of the FOXO4 protein. The exact sequence is published in the 2017 Cell paper by Baar et al. It is written using D-amino acid abbreviations and is not the same as the natural L-amino acid sequence.
Is FOXO4-DRI safe for humans?
FOXO4-DRI is not FDA-approved for human use and has not completed human trials. Its side effects in humans are unknown. Anyone considering it should consult a licensed healthcare professional.
Where can I find FOXO4-DRI dosage information?
No standard FOXO4-DRI dosage exists for humans because it is not approved for clinical use. Dosage information found online is anecdotal and not supported by controlled trials. Always consult a healthcare professional before using any unapproved peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.